Drug profile

The FDA adverse-event record for Trimeprazine Tartrate;Prednisolone

315 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Trimeprazine Tartrate;Prednisolone. See the species affected, top reactions, and outcomes below.

315
adverse-event reports
11.7%
death-coded share
Dog
most-reported species
64
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
315
Total Reports
37
Deaths Reported
11.7%
Death Rate

Active Ingredients

Trimeprazine Tartrate;Prednisolone

Administration Routes

OralUnknown

Species Affected

Dog 294
Unknown 19
Other 1
Cat 1

Most Affected Breeds

Chihuahua 24
Retriever - Labrador 22
Unknown 20
Shih Tzu 18
Maltese 13
Dog (unknown) 13
Terrier - Yorkshire 12
Retriever - Golden 10
Bulldog - French 10
Shepherd Dog - German 9

Most Reported Reactions

Lack of efficacy - NOS 64
Vomiting 41
Lethargy (see also Central nervous system depression in 'Neurological') 36
Diarrhoea 26
Panting 22
Cough 22
Seizure NOS 20
Death 19
Polydipsia 19
Anorexia 17
Elevated serum alkaline phosphatase (SAP) 17
Polyuria 17

Outcome Breakdown

Ongoing
185 (62.5%)
Outcome Unknown
45 (15.2%)
Recovered/Normal
28 (9.5%)
Died
22 (7.4%)
Euthanized
15 (5.1%)
Recovered with Sequela
1 (0.3%)

Trimeprazine Tartrate;Prednisolone Adverse Event Insights

315 reports name Trimeprazine Tartrate;Prednisolone; 37 recorded a death outcome (11.7% of reported events, not a population-level mortality rate). Active ingredient: Trimeprazine Tartrate;Prednisolone. Administration routes: Oral, Unknown.

By species: Dog (294 reports), Unknown (19 reports), Other (1 reports). By breed: Chihuahua (24), Retriever - Labrador (22), Unknown (20).

Leading clinical signs: Lack of efficacy - NOS (64), Vomiting (41), Lethargy (see also Central nervous system depression in 'Neurological') (36), Diarrhoea (26). Outcome, 296 coded reports: Ongoing leads at 62.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.